ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005093

skin disorder

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. skin disorder. Diseases, record MONDO_0005093. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005093

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
skin disorder
Open Targets
Open Targets ID
MONDO_0005093
Open Targets
Other names
SKIN AND SUBCUTANEOUS TISSUE DISORDERS, cutaneous disorder, disease of zone of skin, disease or disorder of zone of skin, disorder of skin, disorder of zone of skin, skin disease, skin diseases and manifestations, zone of skin disease, zone of skin disease or disorder
Open Targets
Disease Ontology
DOID:37
Disease Ontology
MeSH
D012871
MeSH
NCI Thesaurus
C3371
NCI Thesaurus
Highest stage of its drugs
Approval, for 32 of its 44 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
Open Targets

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
FLUOCINONIDECHEMBL1501Small moleculeApprovalDailyMed411Drugs and targets
FLUTICASONE PROPIONATECHEMBL1473Small moleculeApprovalDailyMed1200Drugs and targets
CLOBETASOL PROPIONATECHEMBL1159650Small moleculeApprovalDailyMed1100Drugs and targets
MOMETASONE FUROATECHEMBL1161Small moleculeApprovalDailyMed800Drugs and targets
HYDROCORTISONECHEMBL389621Small moleculeApprovalDailyMed500Drugs and targets
HYDROCORTISONE BUTYRATECHEMBL1683Small moleculeApprovalDailyMed500Drugs and targets
TRIAMCINOLONE ACETONIDECHEMBL1504Small moleculeApprovalDailyMed500Drugs and targets
BETAMETHASONE DIPROPIONATECHEMBL1200384Small moleculeApprovalDailyMed400Drugs and targets
BETAMETHASONE VALERATECHEMBL1497Small moleculeApprovalDailyMed400Drugs and targets
FLURANDRENOLIDECHEMBL1201012Small moleculeApprovalDailyMed400Drugs and targets

1 to 10 of 44

See all 44 drugs

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
NR3C1Glucocorticoid receptor22Glucocorticoid receptor agonistApprovalhttps://conductscience.org/library/genes/2908Drugs and targets
HRH1Histamine H1 receptor7Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonistApprovalhttps://conductscience.org/library/genes/3269Drugs and targets
ADRA2AAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistApprovalhttps://conductscience.org/library/genes/150Drugs and targets
ADRA2BAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistApprovalhttps://conductscience.org/library/genes/151Drugs and targets
ADRA2CAdrenergic receptor alpha-21Adrenergic receptor alpha-2 agonistApprovalhttps://conductscience.org/library/genes/152Drugs and targets
IMPDH1Inosine-5'-monophosphate dehydrogenase (IMPDH)1Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorPhase 1https://conductscience.org/library/genes/3614Drugs and targets
IMPDH2Inosine-5'-monophosphate dehydrogenase (IMPDH)1Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorPhase 1https://conductscience.org/library/genes/3615Drugs and targets
JAK1Janus Kinase (JAK)1Janus Kinase (JAK) inhibitorPhase 1/2https://conductscience.org/library/genes/3716Drugs and targets
JAK2Janus Kinase (JAK)1Janus Kinase (JAK) inhibitorPhase 1/2https://conductscience.org/library/genes/3717Drugs and targets
JAK3Janus Kinase (JAK)1Janus Kinase (JAK) inhibitorPhase 1/2https://conductscience.org/library/genes/3718Drugs and targets

1 to 10 of 16

See all 16 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT03873987Relative Exposure and Safety Study of Kimyrsa in ABSSSI PatientsPhase 11022021-04-13Acute Bacterial Skin and Skin Structure InfectionORITAVANCINOpen Targets' reading of its recordClinicalTrials.gov
NCT00667589Sorafenib-induced Hand- Foot Skin Reaction TreatmentPhase 262013-05-27Hand-foot Skin Reaction, RashFLUOCINONIDE, TAZAROTENE, UREAOpen Targets' reading of its recordClinicalTrials.gov
NCT02968446Effect of Vitamin D After Application With ValchlorEarly phase 133Skin IrritationCHOLECALCIFEROLOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT00433186Mycophenolate Mofetil in Systemic SclerosisPhase 130Diffuse Cutaneous Systemic SclerosisMYCOPHENOLATE MOFETILIts record names the diseaseClinicalTrials.gov
NCT03054259Rituximab Objective Outcome Measures Trial in SLEPhase 230Systemic Lupus Erythematosus ArthritisRITUXIMABIts record names the diseaseClinicalTrials.gov
NCT05104723Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory ComplicationsPhase 1/210Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung DiseaseTOFACITINIBIts record names the diseaseClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Orbactiv vs Kimrysa: deaths from any cause0 of 520 of 50102NCT03873987Trial comparisons
Orbactiv vs Kimyrsa: Number of Subjects With at Least One Treatment Emergent Adverse Event (TEAE)31 of 5224 of 50102NCT03873987Trial comparisons
Orbactiv vs Kimrysa: serious adverse events1 of 522 of 50102NCT03873987Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing it
36692020DERIVED1

Source PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005093

GET https://conductscience.org/api/diseases/v1/MONDO_0005093/drugs?page=2

API referenceFor AI assistants